Genomics of prostate cancer: Is there anything to "translate"?

Pathology and Oncology Research

Volumn 11, Issue 4, 2005, Pages 197-203

  Kopper, László ^a   Tímár, József ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Genomics; Progression; Prostate cancer; Proteomics

Indexed keywords

CANCER GENETICS; CANCER GROWTH; CELL FUNCTION; CELL GROWTH; DIAGNOSTIC VALUE; DNA MICROARRAY; EPIGENETICS; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HUMAN; PHENOTYPE; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; RELIABILITY; REPRODUCIBILITY; REVIEW; STANDARDIZATION;

EID: 33144487134     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893851     Document Type: Review

References (66)

1. Arakawa A, Soh S, Chakaborty S, et al: Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 antigen). Prostate Cancer Prostatic Dis 1:32-38, 1997
2. Ashida S, Nakagawa H, Katagiri T, et al: Molecular features of the transition from prostate intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64:5963-5972, 2004
3. Banez LL, Srivastava S, Moul JW: Proteomics in prostate cancer. Curr Opin Urol 15:151-156, 2005
4. Bernard D, Pourtier-Manzanedo A, Gil J and Beach DH: Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 112:1724-1731, 2003
5. Calvo A, Gonzales-Moreno O, Yoon C-Y, et al: Prostate cancer and the genomic revolution: Advances using microarray analyses. Mutat Res 576:66-79, 2005
6. Chen G, Shukeir N, Potti A, et al: Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101:1345-1356, 2004
7. Chiorino G, Acquadro F, Mello Grand M, et al: Interpretation of expression-profiling results obtained from different platforms and tissue sources: examples using prostate cancer data. Eur J Cancer 40:2592-2603, 2004
8. DeMarzo AM, Nelson WG, Isaacs WB, et al: Pathological and molecular aspects of prostate cancer. Lancet 361:955-964, 2003
9. Deutsch E, Maggiorella L, Eschwege P, et al: Environmental, genetic and molecular features of prostate cancer. Lancet Oncol 5:303-313, 2004
10. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826, 2001
11. Di Lorenzo G, Tortora G, D'Armiento F, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8:3438-3444, 2002
12. Dong Y, Zhang H, Hawthorn L, et al: Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63: 52-59, 2003
13. Edwards J, Krishna NS, Witton CJ and Bartlett JMS: Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9:2571-2581, 2003
14. Edwards SM, Eeles RA: Unravelling the genetics of prostate cancer. Am J Med Genet C, Semin Med Genet 129:65-73, 2004
15. Furuya Y, Nagakawa O and Fuse H: Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer. Endocrine J 50:629-633, 2003
16. Glinsky GV, Glinskii AB, Stephenson AJ, et al: Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113:913-923, 2004
17. Gravdal K, Halvorsen OJ, Haukaas SA and Akslen LA: Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progression in localized prostate cancer. Virchows Arch, 2005 (in press)
18. Gregory CW, Fei X, Ponguta L, et al: Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 179:7119-7130, 2004
19. Gsur A, Feik E, Madersbacher S: Genetic polymorphisms and prostate cancer risk. World J Urol 21:414-423, 2004
20. Henshall SM, Afar DEH, Hiller J, et al: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63:4196-4203, 2003
21. Hughes C, Murphy A, Martin C, et al: Molecular pathology of prostate cancer. J Clin Pathol 58:673-684, 2005
22. Jennbacken K, Vallbo C, Wang W and Damber JE: Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 65:110-116, 2005
23. Jung K, Lein M, Stephan C, et al: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111:783-791, 2004
24. Karayi MK, Markham AF: Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis 7:6-20, 2004
25. Kaushal V, Mukunyadzi P, Dennis RA, et al: Stage-specific characterization of the vascular endothelia growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 11:584-593, 2005
26. Keshava C, McCanlies EC, Weston A: CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 160:825-841, 2004
27. Kil PJ, Goldschmidt HM, Wieggers BJ et al: Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma. Eur Urol 43:31-38, 2003
28. Klezovitch O, Chevillett J, Mirosevitch J, et al: Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6:186-195, 2004
29. Koivisto PA, Hyytinen ER, Matikainen M, et al: Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer. J Urol 171:431-433, 2004
30. Kwak C, Jeong SJ, Park MS, et al: Prognostic significance of the nadir prostate specific antigen after hormone therapy for prostate cancer. J Urol 168:995-1000, 2002
31. Lara PN Jr, Meyers FJ, Gray CR, et al: Her-2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer 94:2584-2589, 2002
32. Lehrer S, Diamond EJ, Mamkine B, et al: Serum interleukin-8 is elevated in men with prostate cancer bone metastases. Technol Cancer Res Treat 3:411, 2004
33. Li LC, Okino ST, Dahiya R: DNA methylation in prostate cancer. Biophys Biochem Acta 1704:87-102, 2004
34. Li Y, Sarkar FH: Gene expression profiles of genistein-treated PRCA3 prostate cancer cells. J Nutr 132:3623-3631, 2002
35. Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2. J Clin Oncol 22: 735-742, 2004
36. Lorenzo GD, Bianco R, Torora G and Ciardillo F: Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2:50-57, 2003
37. Mehta PB, Jenkins BL, McCarthy L, et al: MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22:1381-1389, 2003
38. Miyata Y, Sakai H, Hayashi T and Kanetake H: Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54:125-132, 2003
39. Mohler JL, Gregory CW, Ford III OH, et al: The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448, 2004
40. Nakamura T, Scorilas A, Stephan C, et al: Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 88:1101-1104, 2003
41. Nakayama M, Gonzalgo, Yegnasubramanian S, et al: GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 91:540-552, 2004
42. Nie D, Che M, Zacharek A, et al: Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 164:429-439, 2004
43. Offesen BV, Borre M, Brandt F, et al: Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis. APMIS 110:177-185, 2002
44. Porkka KP, Visakorpi T: Molecular mechanisms of prostate cancer. Eur Urol 45:683-691, 2004
45. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350:1655-1664, 2004
46. Ross JS, Kallakury BV, Sceehan CE, et al: Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10:2466-2472, 2004
47. Rubin MA, Buyyounouski M, Bagiella E, et al: Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53:542-547, 1999
48. Rubin MA, Mucci NR, Figurski J, et al: E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 32:690-697, 2001
49. Shappell SB, Manning S, Boeglin W, et al: Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3:287-303, 2001
50. Shariat SF, Roudier MP, Wilcox GE, et al: Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res 63:4662-4671, 2003
51. Stefanou D, Batistatou A, Kamina S, et al: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 18:155-160, 2004
52. Stewart DA, Cooper CR and Sikes RA: Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2:1-14, 2004
53. Straume O, Chappuis PO, Salvesen HB, et al: Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 62:6808-6811, 2002
54. Subbarayan V, Xu XC, Kim J, et al: Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7:280-293, 2005
55. Thompson J, Hyytinen ER, Haapala K, et al: Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab Invest 83:1709-1713, 2003
56. Tímár J, Rásó E, Döme B, et al: Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 87:37-43, 2000
57. Trikha M, Tímár J, Lundy SK, et al: Human prostate carcinoma cells express functional αIIbβ3 integrin. Cancer Res 56:5071-5078, 1996
58. Uzgare AR, Isaacs JT: Enhanced redundancy in Akt and mitogen-activated protein-kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 64:6190-6199, 2004
59. Uzgare AR, Isaacs JT: Prostate cancer: potential targets of antiproliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 37:707-714, 2005
60. Wang W, Bergh A and Damber JE: Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11:3250-3256, 2005
61. Welch DR and Hunger KW: A new member of the growing family of metastasis suppressors identified in prostate cancer. J Natl Cancer Inst 95:839-891, 2003
62. Xin W, Rhodes DR, Ingold C, et al: Dysregulation of annexin family is associated with prostate cancer progression. Am J Pathol 162:255-261, 2003
63. Yu EY, Yu E, Meyer GE and Brawer MK: The relation of p53 protein nuclear accumulation and angiogenesis in human prostatic carcinoma. Prostate Cancer Prostatic Dis 1:39-44, 1997
64. Yu YP, Landsittel D, Jing L, et al: Gene expression alteration in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22:2790-1799, 2004
65. Zellweger T, Ninck C, Mirlacher M, et al: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 55:20-29, 2003
66. Zeng Y, Opeskin K, Baldwin ME, et al: Expression of vacular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 10:5137-5144, 2004